AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30002865
Drug: AbobotulinumtoxinA injections
RxNorm normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: AbobotulinumtoxinA injections
Trial: 23577077
Drug: Oxycodone at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone at a fixed dose with increasing pregabalin doses (Arm A)
Trial: 23577077
Drug: Pregabalin at
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin at a fixed dose with increasing oxycodone doses (Arm B)
Trial: 18955945
Drug: Ziprasidone, median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone, median dose 120 mg/day at endpoint
Trial: 12814389
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 30)
Trial: 10770814
Drug: Elective anti-pseudomonal
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elective anti-pseudomonal antibiotic treatment (4 treatments per year)
Trial: 10770814
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment (3 treatments per year)
Trial: 1632252
Drug: Erythromycin 0.5
RxNorm normalized name: ERYTHROMYCIN 0.5% OINT,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 0.5 g x 2
Trial: 6742612
Drug: Methylprednisolone (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (16 mg/day given orally for 7 days)
Trial: 30562392
Drug: Magne B6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magne B6 (Mg–vitamin B6); daily dose 300 mg magnesium and 30 mg vitamin B6
Trial: 30562392
Drug: Magnespasmyl (Mg);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnespasmyl (Mg); daily dose 300 mg magnesium
Trial: 30562392
Drug: Magne B6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magne B6 (Mg–vitamin B6)
Trial: 30562392
Drug: Magnespasmyl (Mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnespasmyl (Mg)
Trial: 25599775
Drug: Ketamine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine + Propofol (0.5 mg/kg ketamine + 1 mg/kg propofol)
Trial: 25599775
Drug: Alfentanil +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil + Propofol (10 mg/kg alfentanil + 1 mg/kg propofol)
Trial: 11860726
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g dried plums
Trial: 11860726
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g dried apples
Trial: 10103297
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (250 microg/dose)
Trial: 10103297
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1 mL/dose)
Trial: 6137307
Drug: Leucine infusion
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine infusion (300 mumol/min for 150 min)
Trial: 6137307
Drug: Leucine plus
RxNorm normalized name: Leucine
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leucine plus glucose infusion (2.2 mmol/min)
Trial: 6137307
Drug: Leucine, somatostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucine, somatostatin (7 micrograms/min) and glucagon (1 ng/min) infusion
Trial: 29793558
Drug: Specialised Treatment
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialised Treatment for Severe Bodily Distress Syndromes (STreSS)
Trial: 23975354
Drug: Acute treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute treatment for adolescent depression for 12 weeks followed by an additional 12 weeks of treatment.
Trial: 22180621
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment (IT) - 36 weeks of antiretrovirals
Trial: 22180621
Drug: Deferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred treatment (DT) - no treatment initially
Trial: 17696268
Drug: Computer tool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer tool designed to elicit preferences based on patient tradeoffs for treatment options.
Trial: 11960953
Drug: ACh infusion
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACh infusion
Trial: 11960953
Drug: Nitroprusside (NTP)
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nitroprusside (NTP) infusion
Trial: 9858440
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg once a day for 14 days
Trial: 9858440
Drug: Piroxicam 20
RxNorm normalized name: piroxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam 20 mg once a day for 28 days
Trial: 43255
Drug: Penbutolol (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (0.08 mg/kg i.v.)
Trial: 43255
Drug: Alprenolol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol (0.4 mg/kg i.v.)
Trial: 43255
Drug: Propranolol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.4 mg/kg i.v.)
Trial: 43255
Drug: Propranolol (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (160 mg b.i.d. orally)
Trial: 43255
Drug: Alprenolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprenolol (400 mg b.i.d. orally)
Trial: 43255
Drug: Penbutolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penbutolol (40 mg b.i.d. orally)
Trial: 31481375
Drug: s-ketamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s-ketamine (0.25 mg/kg bolus followed by 0.1 mg/kg/hour continuous infusion)
Trial: 25679340
Drug: Real rTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rTMS (1 Hz, 15 min) followed by 45 min physical therapy
Trial: 17705695
Drug: Pioglitazone (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-30 mg/day) as add-on therapy to metformin or SU
Trial: 17705695
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of metformin (400 mg) and glibenclamide (2.5 mg)
Trial: 11245756
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups performed 5 cycles of a 2‐second contraction with 22‐second rest periods between agonist muscle contractions.
Trial: 10660974
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg t.i.d. (n = 14)
Trial: 7887022
Drug: EcSf2a-2 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EcSf2a-2 vaccine (4 doses, 4.1 x 10(8) to 1.1 x 10(9) c.f.u.)
Trial: 18573718
Drug: 3.5 mM
RxNorm normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5 mM TauBr cream
Trial: 18573718
Drug: 1% Clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Clindamycin gel (Clindacin T)
Trial: 10731011
Drug: NaHCO3 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (0.3 g x kg(‐1))
Trial: 10731011
Drug: NaCl (0.21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (0.21 g x kg(‐1))
Trial: 1382132
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three antihistamines (Cetirizine, Promethazine, Chlorpheniramine)
Trial: 3515919
Drug: Flurbiprofen (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (50 mg orally twice a day)
Trial: 3515919
Drug: Sulindac (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulindac (150 mg orally twice a day)
Trial: 29915914
Drug: Control (non-users
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-users of aspirin)
Trial: 26663880
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg, then 150 mg d(-1)) plus Aspirin (100 mg d(-1))
Trial: 26663880
Drug: Ticagrelor (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (180 mg) plus Aspirin (300 mg)
Trial: 26663880
Drug: Ticagrelor plus
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor plus Aspirin
Trial: 15942159
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran supplement (2 oat bran-enriched muffins per day, 28 g/day of oat bran)
Trial: 15942159
Drug: Oat bran
RxNorm normalized name: Oat bran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat bran supplement
Trial: 10464004
Drug: Transdermal glyceryl‐trinitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl‐trinitrate (24 h/day)
Trial: 10464004
Drug: Transdermal glyceryl‐trinitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl‐trinitrate (16 h/day)
Trial: 7628025
Drug: Rectal thiopentone
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal thiopentone 35 mg.kg‐1
Trial: 2127268
Drug: Cefpodoxime proxetil,
RxNorm normalized name: Cefpodoxime Proxetil, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil, 5-day treatment
Trial: 2127268
Drug: Penicillin, 10-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Penicillin, 10-day treatment
Trial: 26275480
Drug: PPV23 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPV23 vaccine
Trial: 21844413
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for acute rhinosinusitis
Trial: 19828373
Drug: Fatigue at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fatigue at the end of treatment as a predictive variable for persistent fatigue
Trial: 16768837
Drug: Fructo-oligosaccharides (FOS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructo-oligosaccharides (FOS) 25-30 g/d
Trial: 11642626
Drug: Hib conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hib conjugate vaccines (HbOC or Hib-OMP)
Trial: 11642626
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (PnPs)
Trial: 9539303
Drug: Cabergoline (CAB)
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline (CAB) at a dose of 0.5-1.5 mg/week (n = 7)
Trial: 9539303
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine (BRC) at a dose of 5-15 mg/day (n = 10)
Trial: 2816802
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg zinc (gluconate)
Trial: 19015347
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg of body weight weekly (arm A)
Trial: 19015347
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg loading dose followed by 6 mg/kg every 2 weeks (arm B)
Trial: 19015347
Drug: 25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg every 2 weeks for five doses (arm C)
Trial: 9423751
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride 200 mg/day
Trial: 9423751
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride 600 mg/day
Trial: 9423751
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (Premarin 0.625 mg/day)
Trial: 8423538
Drug: Triazolam (0.1‐0.32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.1‐0.32 mg/70 kg)
Trial: 8423538
Drug: d‐Amphetamine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐Amphetamine (5 and 20 mg/70 kg)
Trial: 28368869
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy administered in 12 one-hour sessions over a 1-month period.
Trial: 19262229
Drug: Nicorandil (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (15 mg/day)
Trial: 18295282
Drug: Buccal mucosa
RxNorm normalized name: Diazepam 5 MG Buccal mucosa Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal mucosa grafts
Trial: 18295282
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Buccal mucosa and Acellular bladder matrix)
Trial: 10817717
Drug: Oral dOTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dOTC (800 mg)
Trial: 10817717
Drug: Intravenous dOTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dOTC (100 mg)
Trial: 8751401
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (RT) consisting of intracavitary brachytherapy alone to a median dose of 21 Gy for 17 patients.
Trial: 8751401
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (RT) consisting of external beam RT to a median dose of 45 Gy followed by intracavitary brachytherapy to a median dose of 12 Gy for 81 patients.
Trial: 6137427
Drug: Solpadeine (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solpadeine (paracetamol 500 mg, codeine phosphate 8 mg, caffeine 30 mg)
Trial: 6137427
Drug: Soluble DNP
RxNorm normalized name: DNP-VACC
DrugBank: Autologous DNP-conjugated tumour vaccine (DB17361)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble DNP (dextropropoxyphene napsylate equivalent to 32.5 mg hydrochloride and paracetamol 325 mg)
Trial: 30858609
Drug: 4400 IU
RxNorm normalized name: Ascorbic Acid/Biotin/Calcium/Calcium Pantothenate/Chloride/Chromium/Copper/Cyanocobalamin/Folic Acid/Iodine/Iron/Magnesium/Manganese/Molybdenum/Niacinamide/Phosphorus/Phytonadione/Potassium/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 120 MG-0.015 MG-40 MG-10 MG-6.8 MG-0.015 MG-2 MG-0.009 MG-0.4 MG-0.15 MG-27 MG-100 MG-5 MG-0.015 MG-30 MG-31 MG-0.028 MG-7.5 MG-3 MG-3.4 MG-0.01 MG-3 MG-4400 IU-400 IU-30 IU-15 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4400 IU vitamin D daily
Trial: 30858609
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU vitamin D daily (Control)
Trial: 29774628
Drug: brexpiprazole 2
RxNorm normalized name: brexpiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 2 mg
Trial: 29774628
Drug: brexpiprazole 4
RxNorm normalized name: brexpiprazole 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 4 mg
Trial: 26301771
Drug: brexpiprazole 1
RxNorm normalized name: brexpiprazole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: brexpiprazole 1 mg
Trial: 24457632
Drug: 3-drug therapy
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-drug therapy (N = 14)
Trial: 24457632
Drug: 5-drug therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-drug therapy (N = 26)
Trial: 20595280
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (weekly attention-control phone calls)
Trial: 11491010
Drug: albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albendazole 400 mg with ivermectin 200 micrograms/kg
Trial: 11491010
Drug: albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: albendazole 400 mg with diethylcarbamazine citrate (DEC) 6 mg/kg
Trial: 11491010
Drug: albendazole 600
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: albendazole 600 mg with ivermectin 400 micrograms/kg
Trial: 8319375
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Trial: 3520133
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg BAYo1248 administered prior to breakfast
Trial: 3520133
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg BAYm1099 administered prior to breakfast, lunch, and dinner
Trial: 30504569
Drug: Gabapentin (2400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (2400 mg/d, tid) + pulsed radiofrequency lesioning of the dorsal root ganglion
Trial: 30504569
Drug: Oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral gabapentin (2400 mg/d, tid)
Trial: 27240921
Drug: Oral L-tryptophan
RxNorm normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral L-tryptophan (30, 60 or 120 mg/kg body weight)
Trial: 25630245
Drug: Antagonist passive
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antagonist passive static stretching (AS) for 40 seconds applied to pectoralis major prior to each set of seated row (SR)
Trial: 25630245
Drug: Antagonist passive
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Antagonist passive static stretching (AS)
Trial: 20619837
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of atorvastatin and fenofibrate
Trial: 18199184
Drug: Solution-focused group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused group therapy (SFGT)
Trial: 18199184
Drug: Traditional problem-focused
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional problem-focused treatment
Trial: 16523206
Drug: EFA‐supplemented test‐treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFA‐supplemented test‐treatment formula
Trial: 8646820
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of midazolam (2 mg)
Trial: 8646820
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of midazolam (1 mg)
Trial: 22434523
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (daily calcium 1 g and vitamin D(3) 800 IU, plus additional oral 16,000 IU every 2 weeks if baseline 25(OH)D <30 ng/ml)
Trial: 21245499
Drug: CC extension
RxNorm normalized name: EXTENSION TUBES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC extension
Trial: 21245499
Drug: CC flexion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC flexion
Trial: 21245499
Drug: Extensor to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensor to flexor strength ratio at CC axis
Trial: 1460158
Drug: Integrated systemic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated systemic therapy (IST)
Trial: 6425033
Drug: One nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One nitroglycerin plaster (5 mg liberation within 24 hours)
Trial: 6425033
Drug: Two nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two nitroglycerin plasters (5 mg liberation within 24 hours)
Trial: 6425033
Drug: Four nitroglycerin
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four nitroglycerin plasters (5 mg liberation within 24 hours)
Trial: 6425033
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg 5‐isosorbide mononitrate (ISMN)
Trial: 27941179
Drug: Safflower oil
RxNorm normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safflower oil treatment for three months
Trial: 21166343
Drug: Fluoxetine hydrochloride
RxNorm normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine hydrochloride for 3 months
Trial: 12503837
Drug: Olanzapine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (5 mg/day titrated to 20 mg/day)
Trial: 24006861
Drug: Topical ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular hypotensive medication for 12 weeks